|
|
Medistem to Present on Its Progress in Its Menstrual Derived Stem Cell Program ERC ; BioFinance 2008 Presentation to Highlight ERC Clinical Path
- Article from:
-
CCNMatthews Newswire
- Article date:
-
May 6, 2008
|
Copyright informationCopyright 2008 CCNMatthews Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
SAN DIEGO, CA and SCOTTSDALE, AZ--(Marketwire - May 06, 2008) -
Medistem Laboratories, Inc. (OTCBB: MDSM), a biotechnology company
dedicated to commercialization of its novel, universal donor, stem
cell population, the Endometrial Regenerative Cell (ERC), is pleased
to announce its upcoming presentation at the BioFinance 2008
meeting.
Medistem will review its recent progress in the development of an
"off the shelf" product for the treatment of critical limb ischemia,
an advanced form of peripheral vascular disease. The company will
also provide an overview of its current scientific and regulatory
strategy, as well as its ongoing research efforts.
Thomas Ichim, CEO of Medistem, commented, ...